Podol'tseva E I, Morozova E V, Almazov V A
Vopr Onkol. 1996;42(4):32-5.
Serum levels of beta 2-microglobulin (beta 2-M) have been assayed in 50 patients with multiple myeloma (MM) (stage 1-8, stage II-25. stage III - II and remission - 6). Smoldering MM was registered in 11 cases, active - 22 and aggressive - 17. Said level was significantly higher in MM patients than in healthy donors (p < 0,01) and correlated with stage and course in most cases: blood concentration of beta 2-M at stage I and in remission was found to be significantly lower than at stage II and III (p < 0,05, p < 0,05) while at stage III - higher than at stage II (p < 0,01). Serum level of beta 2-M was significantly higher in smoldering course than in healthy donors (p < 0,05) and lower than in active (p < 0,05) and aggressive MM (p < 0.01). Said concentration in blood proved significantly higher in aggressive course than in active MM (p < 0,05). Since some cases of active and aggressive MM revealed a low level of serum beta 2-M, reliance on this index as a sole prognostic test seems doubtful.
对50例多发性骨髓瘤（MM）患者（Ⅰ期18例、Ⅱ期25例、Ⅲ期7例、缓解期6例）的血清β2-微球蛋白（β2-M）水平进行了检测。其中冒烟型MM 11例，活动型22例，侵袭型17例。MM患者的该水平显著高于健康供者（p<0.01），且在大多数情况下与分期及病程相关：Ⅰ期及缓解期患者血液中β2-M浓度显著低于Ⅱ期及Ⅲ期患者（p<0.05，p<0.05），而Ⅲ期患者高于Ⅱ期患者（p<0.01）。冒烟型病程患者血清β2-M水平显著高于健康供者（p<0.05），但低于活动型（p<0.05）及侵袭型MM患者（p<0.01）。侵袭型病程患者血液中的该浓度显著高于活动型MM患者（p<0.05）。由于部分活动型及侵袭型MM患者血清β2-M水平较低，因此仅依靠该指标作为唯一的预后检测指标似乎并不可靠。
